Fig. 2

Primary efficacy and subgroup analysis outcomes at the 12-month follow-up. a Comparison of the minimum FCT at baseline and at the 12-month follow-up. Baseline minimum FCT was comparable between the TXL and placebo groups. After 12 months of treatment, FCT increased significantly in both groups, with a greater extent in the TXL group. Data are presented as the median with 95% CI, n = 110 per group, ***P < 0.001. b Subgroup analysis of the treatment effect on the change in FCT. Treatment differences (TXL minus Placebo) in least-squares mean change from baseline in FCT are shown. The P values for interaction were provided. No significant difference in treatment effect was observed among patients stratified according to age, sex, type 2 diabetes mellitus, lesion category by coronary angiography, baseline LDL-C, statin intensity, and prior statin use. ^a: QCA: quantitative coronary angiography; ^b: Category 1 lesions: stenotic lesions with diameter stenosis < 70% not requiring stent implantation; ^c: Category 2 lesions: stenotic lesions with diameter stenosis ≥ 70% that were stented, as well as plaques in other coronary vessels not requiring PCI; ^d: Category 3 lesions: stenotic lesions with diameter stenosis ≥ 70% that were stented and lesions in the same coronary artery located at least 5 mm from the stent edge and not requiring PCI; ^e: Prior statin use: prior statin use ≥ 4 weeks before enrollment. c: Distribution of angina pectoris severity per the Canadian Cardiovascular Society (CCS) Classification. Bar graphs show the percentage of patients in each CCS (I-V) grading at baseline and at the 12-month follow-up for both the TXL and placebo groups. At the end of the 12-month follow-up, the proportion of patients with CCS Grade I angina was significantly greater in the TXL group (92.3%) than in the placebo group (63.2%, P < 0.001). TXL: Tongxinluo; CCS: Canadian Cardiovascular Society; FCT: fibrous cap thickness